Nk-dli for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 3 Oct 2017: Trial registered, NCT03300492
  2. 12 Nov 2018: Trial started, NCT03300492

The trials

NCT03300492: Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS

State
Under way
Phase
Phase 1 and Phase 2
People
10 planned
Started
12 Nov 2018
Primary completion
31 Dec 2026
Arms
NK-DLI
Results
None posted
  1. 3 Oct 2017: Trial registered
  2. 12 Nov 2018: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.